Senti Biosciences Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $14.1 million for the period ending March 31, 2025. The company's cash and cash equivalents stood at approximately $33.8 million as of March 31, 2025. Research and development expenses increased to $9.3 million from $8.8 million in the same period of 2024, primarily due to a $1.4 million rise in external services and supplies costs, partially offset by a decrease of $0.8 million in personnel-related expenses. General and administrative expenses slightly decreased to $7.1 million from $7.5 million, attributed to a $0.9 million reduction in personnel-related costs, counterbalanced by a $0.5 million increase in external services and supplies costs. In a significant business update, Senti Biosciences shared positive Phase 1 data from its lead program, SENTI-202, at the AACR Annual Meeting. The data showed that SENTI-202 was generally well tolerated, with 4 out of 7 patients achieving composite Complete Remission, all of whom were measurable residual disease negative. These patients have been maintaining responses from 4+ to 8+ months ongoing. The company continues to enroll patients in the Phase 1 study to confirm the preliminary recommended Phase 2 dose, indicating potential for broad liquid and solid tumor applications.